| Test | Result | Normal Range | Status | Trend |
|---|---|---|---|---|
| White Blood Cells | 7.2 K/μL | 4.0-11.0 K/μL | Normal | → Stable |
| Red Blood Cells | 4.1 M/μL | 3.8-5.2 M/μL | Normal | ↓ Slight decline |
| Hemoglobin | 10.8 g/dL | 12.0-16.0 g/dL | Low ⚠️ | ↓ Declining |
| Hematocrit | 32.1% | 36.0-48.0% | Low ⚠️ | ↓ Declining |
| Platelets | 285 K/μL | 150-450 K/μL | Normal | → Stable |
| Total Cholesterol | 248 mg/dL | <200 mg/dL | High 🚨 | ↑ Rising |
| Iron | 45 μg/dL | 60-170 μg/dL | Low ⚠️ | ↓ Declining |
| Ferritin | 8 ng/mL | 15-150 ng/mL | Low ⚠️ | ↓ Critically low |
INTEGRATED FINDINGS
Lab Evidence: Low Hemoglobin (10.8), Hematocrit (32.1%), Iron (45), Ferritin (8)
Supporting Symptoms: Fatigue (6/10, increasing), Dizziness (3/10), correlating with declining lab values
Wearable Data: Decreased step count (-22%), increased resting HR (+8 bpm), poor sleep quality
Lab Evidence: Total Cholesterol 248 mg/dL (24% above target)
Current Treatment: Atorvastatin 20mg (started May 2025) - may need dose adjustment
Lifestyle Impact: Reduced activity levels may be contributing to lipid elevation
Evaluate atorvastatin effectiveness, consider lifestyle counseling
Symptom Pattern: Joint pain (7/10, worsening) without clear lab inflammation markers
Recommendation: Consider ESR, CRP, and rheumatologic panel
Activity Impact: 35% reduction in active minutes, may be pain-related
BIOSENSOR INSIGHTS
Pattern Detection: 5.2hr avg sleep (↓20% from baseline) correlates with Hemoglobin 10.8 g/dL
Mechanism: Iron deficiency → Poor oxygen delivery → Frequent micro-awakenings → Non-restorative sleep
Deep Sleep Deficit: Only 45min (14%) vs normal 20-25% - directly impacts cellular repair and recovery
Predictive Value: Each 1g/dL drop in Hgb correlates with ~15min less deep sleep in this patient
Iron supplement timing: Move to 2 hours before bed to improve absorption and reduce GI distress affecting sleep
Target bedtime HR: <70bpm using breathing exercises
Monitor: If deep sleep remains <15% after 2 weeks, consider sleep study for restless leg syndrome (common in iron deficiency)
HR Elevation: Resting HR 78bpm (+8 from baseline) indicates cardiac compensation for anemia
HRV Decline: 28ms (↓22%) suggests autonomic dysfunction from combined anemia + poor sleep
Activity Intolerance: Steps decreased 22% when HR exceeds 85bpm during minimal exertion
Risk Factor: Sustained elevated HR + high cholesterol (248) = increased cardiovascular strain
Morning Pattern: Low morning HRV (25ms) predicts joint pain severity (r=0.72)
Step Count Threshold: Days with <4000 steps correlate with next-day fatigue increase
Recovery Marker: SpO2 drops to 95% during sleep on high joint pain days
Intervention Window: Best activity tolerance 2-4pm when ferritin-related fatigue is lowest
TREND TRAJECTORY
6-Month Decline: Hemoglobin ↓18% (12.1→10.8), Iron ↓31% (65→45 μg/dL)
Clinical Significance: Consistent monthly decline suggests ongoing blood loss or malabsorption, not acute event
Risk Stratification: High risk for cardiac complications if Hgb falls below 10 g/dL - consider IV iron if no response in 4 weeks
Treatment Response: Recommend monitoring schedule of weekly CBC x2; then 1x monthly thereafter. Follow up OV in 4 weeks if Hgb decline continues.
Cholesterol Trajectory: 13% increase over 6 months (220→248 mg/dL)
Statin Resistance: Despite atorvastatin since May 15, levels continue rising
Compounding Factors: Reduced activity from anemia may worsen lipid profile
Symptom Onset: Patient fatigue complaints began ~April (correlates with Hgb <11.5)
Critical Threshold: Joint pain emerged when ferritin likely fell below 15 ng/mL (May-June)
Predictive Value: Current trajectory suggests ferritin <5 ng/mL without intervention
Sleep Quality Analysis
-
Iron Sulfate 325mgOnce daily with foodStarted: Jul 20, 2025
-
Atorvastatin 20mgOnce daily at bedtimeStarted: May 15, 2025
-
MultivitaminOnce daily with breakfastStarted: Jan 10, 2025
-
Ibuprofen 400mgAs needed for joint painStarted: Jul 25, 2025